ASS1 and sarcoma: The use of a pegylated arginine deiminase (ADI-PEG20) to pharmacologically deplete exogenous arginine in sarcoma cells (typically ASS1 deficient cells) resulted in prolonged arginine starvation and metabolic stress and had already been tried with promising growth restraining effects [36,73].